Singapore, Feb. 13 -- CARsgen Therapeutics, a company focused on developing innovative CAR T-cell therapies, has announced that through its indirectly wholly-owned subsidiary CARsgen Diagnostics, it has signed Strategic Cooperation Agreements agreements with Shanghai Jingong Enterprise, which is a key platform enterprise in the Bay Area High-Tech Zone of Jinshan District, Shanghai.

With a total investment amount not exceeding RMB370 million, the company will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai.

This move closely aligns with the commercialisation progress of the company's multiple CAR T-cell products, including the marketed product zevorcabtagene autoleucel and the CAR...